Medical Oncology Department, Tanta Cancer Center, Tanta, Egypt.
Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
J Egypt Natl Canc Inst. 2021 Apr 7;33(1):9. doi: 10.1186/s43046-021-00064-6.
Intensive acute lymphoblastic leukemia (ALL) regimens in children improve the 5-year event-free survival (EFS) to reach ~ 90%. Adolescents and young adults (AYA) have EFS (30% to 45%). Young AYA ALL patients treated with pediatric chemotherapy protocols such as Dana Farber Consortium Protocol (DFCP) experience a better prognosis. This study aimed to assess the efficacy [EFS and overall survival (OS)] and the toxicity of DFCP in the treatment of Egyptian AYA with newly diagnosed ALL. A retrospective study was performed on 41 patients with newly diagnosed ALL (15 and 39 years) who were treated with DFCP. EFS and OS were estimated using the Kaplan-Meier method.
Thirty-eight patients (92.68%) achieved complete remission (CR). Eleven patients (26.83%) relapsed. Ten (24.39%) patients died. One, two, and three years of EFS were 75.61%, 72.91%, and 67.51% respectively. One, two, and three years OS were 85.3%, 77.26%, and 74.39% respectively. Neutropenia was the most common adverse event observed in 100% of patients.
DFCP can be considered as an effective ALL protocol for the AYA group of patients with good CR, EFS, and OS rates. DFCP seemed to be feasible in AYA despite the toxicities experienced.
儿童强化急性淋巴细胞白血病（ALL）方案可提高 5 年无事件生存率（EFS）至约 90%。青少年和年轻成人（AYA）的 EFS 为（30%至 45%）。接受儿科化疗方案（如达纳-法伯联盟方案（DFCP））治疗的年轻 AYA ALL 患者预后较好。本研究旨在评估 DFCP 在治疗埃及新诊断 ALL 的 AYA 患者中的疗效[EFS 和总生存率（OS）]和毒性。对 41 例新诊断为 ALL（15 岁和 39 岁）的患者进行了回顾性研究，这些患者接受了 DFCP 治疗。采用 Kaplan-Meier 法估计 EFS 和 OS。
38 例患者（92.68%）获得完全缓解（CR）。11 例患者（26.83%）复发。10 例（24.39%）患者死亡。EFS 的 1、2、3 年分别为 75.61%、72.91%和 67.51%。OS 的 1、2、3 年分别为 85.3%、77.26%和 74.39%。中性粒细胞减少是所有患者均观察到的最常见不良事件。
DFCP 可被视为一种有效的 ALL 方案，适用于 AYA 患者，具有良好的 CR、EFS 和 OS 率。尽管存在毒性，DFCP 似乎对 AYA 可行。
